Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
Mercedes Mitjavila, Paula Jiménez‐Fonseca, Pilar Belló, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 8, pp. 2486-2500
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Gastric neuroendocrine neoplasms
Giuseppe Lamberti, Francesco Panzuto, Marianne Pavel, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 13
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update
Martina Di Franco, Lucia Zanoni, Emilia Fortunati, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 5, pp. 538-550
Open Access | Times Cited: 8
Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety
Pasqualino Malandrino, Tiziana Feola, Nevena Mikovic, et al.
Seminars in Nuclear Medicine (2024) Vol. 54, Iss. 4, pp. 570-580
Closed Access | Times Cited: 4
PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC)
Halfdan Sørbye, Grace Kong, Simona Grozinsky‐Glasberg, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 4
Polymer composite microspheres loading 177 Lu radionuclide for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer
Xiao Liu, Yuhao Li, Ruiman Geng, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 10
Análisis de variables dosimétricas y clínicas en el tratamiento de los tumores neuroendocrinos con [177Lu]Lu-DOTA-TATE
Pablo Mínguez Gabiña, T. Monserrat Fuertes, Borja Santos Zorrozua, et al.
Revista Española de Medicina Nuclear e Imagen Molecular (2025), pp. 500089-500089
Closed Access
Pheochromocytoma in MEN2
Matti L. Gild, Kimchi Do, Venessa Tsang, et al.
Recent results in cancer research/Recent Results in Cancer Research (2025), pp. 211-235
Closed Access
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
Jianming Xu, Lin Shen, Jie Li, et al.
European Journal of Cancer (2025), pp. 115398-115398
Closed Access
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101
Udhayvir Singh Grewal, Olumide B. Gbolahan, Amol Takalkar, et al.
Future Oncology (2025), pp. 1-7
Closed Access
Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study
Mark N. Gaze, Daria Handkiewicz-Junak, Raquel Hladun, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Closed Access
Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET)
Martina Di Franco, Giuseppe Lamberti, Davide Campana, et al.
Seminars in Nuclear Medicine (2025)
Open Access
Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022
Valentina Ambrosini, Martyn Caplin, Justo P. Castaño, et al.
Journal of Neuroendocrinology (2023) Vol. 36, Iss. 1
Closed Access | Times Cited: 9
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients
Norma Bonazzi, Emilia Fortunati, Lucia Zanoni, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 701-701
Open Access | Times Cited: 3
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
Maria Passhak, Mairéad G. McNamara, Richard Hubner, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101836-101836
Closed Access | Times Cited: 7
Toxicity manifestations encountered in peptide receptor radionuclide therapy setting
Rahul V. Parghane, Sandip Basu
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 2
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
Jelka Kuiper, Eline Zoetelief, Tessa Brabander, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 2
The role of combined FDG and SST PET/CT in neuroendocrine tumors
Martina Di Franco, Emilia Fortunati, Lucia Zanoni, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 2
Comparison of 68Ga-DOTANOC and 18F-FDOPA PET/CT for Detection of Recurrent or Metastatic Paragangliomas
Linjie Bian, Junyan Xu, Panli Li, et al.
Radiology Imaging Cancer (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 2
68Ga-DOTATATE and 68Ga-FAPI Imaging in Neuroendocrine Neoplasms of Different Grades
Yue Zhou, Lei Ou, Songke Yu, et al.
Clinical Nuclear Medicine (2024) Vol. 49, Iss. 6, pp. 564-566
Closed Access | Times Cited: 1
Carcinoid crisis: The challenge is still there
Fernando Guerrero‐Pérez, Inmaculada Peiró, J.L. Vercher-Conejero, et al.
Endocrinología Diabetes y Nutrición (2024) Vol. 71, Iss. 6, pp. 263-270
Closed Access | Times Cited: 1
Radio theranostics in paragangliomas and pheochromocytomas
Stefan Prado Wohlwend, Pilar Bello Arques
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) (2024) Vol. 43, Iss. 4, pp. 500017-500017
Closed Access | Times Cited: 1
Maximum tumor diameter and renal function can predict the declining surface dose rate after 177Lu-Dotatate: preliminary results of single institution in Japan
Takashi Ono, Mayumi Ichikawa, Takeo Tanada, et al.
Japanese Journal of Radiology (2024) Vol. 42, Iss. 9, pp. 1031-1037
Open Access | Times Cited: 1
Development of Alginate-Based Biodegradable Radioactive Microspheres Labeled with Positron Emitter through Click Chemistry Reaction: Stability and PET Imaging Study
Arun Gupta, Ji Yong Park, Hyunjun Choi, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 10, pp. 5005-5014
Closed Access | Times Cited: 1
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors
Rushabh Gujarathi, Joseph Tobias, Sara Abou Azar, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 2993-2993
Open Access | Times Cited: 1
Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single‐institution experience and review of the literature
Charlene Yu Lin Tang, Wei Chua, Hian Liang Huang, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 12
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top